生脉注射液联合奥沙利铂抗肿瘤实验研究

目的:观察生脉注射液联合奥沙利铂(Oxalip latin)应用后瘤重抑制率、免疫功能、肝肾功能以及外周血象的变化。方法:建立H22肝癌荷瘤鼠模型后,随机分为5组,对照组、Oxalip latin组、生脉注射液(大、中、小剂量) Oxalip latin组,每组10只。造模次日开始进行干预,对照组、Oxalip latin组、生脉注射液(大、中、小剂量) Oxalip latin组分别予ip等容量5%葡萄糖注射液、Oxalip latin 6 mg/kg、生脉注射液(大14 mL/kg、中7 mL/kg、小3.5 mL/kg剂量) Oxalip latin 6 mg/kg,用药14 d。停药次日处死,观察瘤重抑制率、免疫功能、肝肾功能、外周血细胞变化。结果:(1)生脉注射液联合Ox-alip latin各组肿瘤生长明显低于Oxalip latin组和对照组(均P<0.05);(2)与对照组相比,Oxalip latin组CD3、CD4、CD4/CD8、IgG、ISM值明显降低(P<0.05),而各生脉联合组CD3、CD4、CD4/CD8、IgG、IgM、IgA值明显升高(P<0.05);(3)与对照组相比,Oxalip latin组ALT升高、WBC降低,而各生脉联合组相对于Oxalip latin组ALT降低、WBC升高(P<0.05)。结论:生脉注射液联合奥沙利铂(Oxalip latin)应用抑瘤效果加强、免疫功能提高,毒副反应减少。

Experimental study on anti-tumor efficacy of Shengmai Injection combined with Oxaliplatin

AIM: To observe the changes in tumor-weight-inhibiting rates,immunological function,liver and renal function and the blood cell in the peripheral blood after administration of Shengmai Injection combined with chemotherapeutic agent,Oxaliplatin. METHODS: Hepatoma 22 tumor bearing mice models were established and then divided randomly into five groups,including control group,Oxaliplatin group,Shengmai Injection(high,middle and low dose) combined with Oxaliplatin groups.Each group had 10 mice.The five groups were injected introperitoneally with same amount of 5% glucose injection,Oxaliplatin 6 mg/kg and Shengmai Injection(14 mL/kg,7 mL/kg and 3.5 mL/kg) plus Oxaliplatin 6 mg/kg respectively,once a day for 14 days. After that,mice in the five groups were all killed after being anesthetized and the tumor-weight-inhibiting rates and the index of immunological function,liver and renal function and the blood cell in the peripheral blood were observed. RESULTS: (1) The tumor-weight-inhibiting rates were higher in each Shengmai Injection plus Oxaliplatin group than that in the Oxaliplatin group (P<0.05);(2)Compared with the control group,the level of CD3,CD4,CD4/CD8,IgG and IgM in Oxaliplatin group were lower(P<0.05).But in the three Shengmai Injection groups combined with Oxaliplatin the level of CD3 CD4/CD8,IgG and IgM were higher than that in control group and Oxaliplatin group,which revealed significant difference(both P<0.05).(3) The level of serum ALT was higher in Oxaliplatin group with lower WBC in the peripheral blood.But in the three Shengmai Injection plus Oxaliplatin groups the level of serum ALT were lower and WBC counts were higher than that in the Oxaliplatin group(P<0.05). CONCLUSION:()The anti-tumor efficacy of Oxaliplatin can enhance when combined with Shengmai Injection,at the same time improve immune function and reduce side-effects.